Personalised medicine

Glasgow, Scotland
#Cancer treatment #Health inequalities #Oncology #Personalised medicine #Precision medicine #University of Glasgow

Commission tackles global access to precision cancer treatments

A team of experts from the University of Glasgow will lead a new international effort to improve cancer control and reduce global health inequalities.  Spearheading the new Lancet Oncology Commission focused on cancer genomics and precision oncology, Glasgow researchers will lead an international team of experts over… Read More

#News

Organoids
#Drug development #Drug discovery #Drug screening #Gene editing #In vitro #In vivo #Organoids #Personalised medicine

Gene editing in organoids: accounting for complexity in drug discovery

Oksana Sirenko looks at the advantages and limitations of using organoids from human cell sources in drug development and drug screening.  The genome is the blueprint for life, consisting of genes made up of thousands of pairs of DNA bases. Altering one base pair can drastically change how the gene’s… Read More

#Exclusive Content

#Clarivate #Drug development #Drug discovery #Market reporting #Personalised medicine #Pharmaceuticals

15 drugs likely to be clinical game-changers

A new report highlights promising therapeutic developments for HIV, Parkinson’s disease, Crohn’s disease, alopaecia, multiple myeloma and breast cancer on the horizon, with personalised medicines strongly represented.  Analysts Clarivate have identified 15 late-stage experimental treatments that are each forecast to deliver annual sales of more than $1 billion within five… Read More

#Exclusive Content #Trends & Analysis

Vaccine production
#BioNTech #Cancer immunotherapy #Cancer research #Clinical trials #Immunotherapy #Moderna #mRNA #mRNA-based vaccines #Personalised medicine #UK government

New UK partnership to accelerate mRNA research

It is hoped that a new partnership between the UK government and BioNTech will help accelerate clinical trials of personalised immunotherapies for cancer and infectious disease vaccines.  The agreement means cancer patients will get early access to trials exploring personalised mRNA therapies, like cancer vaccines.  Professor Uğur Şahin, Chief Executive… Read More

#Business & Investment #Cancer Research #News #Trending News

#AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Biopharmaceuticals #Cell and gene therapy #Diversity #Market reporting #Mergers and acquisitions #Personalised medicine #Pharmaceutical industry #Precision medicine

Drug discovery in 2023: Five key predictions

As 2022 draws to a close, life sciences market analysts attempt to correctly predict what the next 12 months might bring to the drug discovery sector. DDW’s Diana Spencer summarises the key trends likely to impact the market in 2023.  1. There will be greater emphasis on diversity in clinical trials A… Read More

#Exclusive Content #Trends & Analysis

Bone marrow organoids
#Blood cancer #Cancer research #Personalised medicine

‘Bone marrow in a dish’ used to study personalised cancer drugs

Scientists from Oxford University and the University of Birmingham have made the first bone marrow ‘organoids’ that include all the key components of human marrow.   The technology allows for the screening of multiple anti-cancer drugs at the same time, as well as testing personalised treatments for individual… Read More

#Cancer Research #News

#Cancer #Cancer research #Cancer vaccine #Chemotherapy #Chemotherapy-resistance #Drug resistance #Epigenetics #Oncology #Personalised medicine

Cancer research drugs: Where is the innovation?

An update on the latest oncology developments by DDW Digital Content Editor Diana Spencer The last month has seen huge strides forward in our understanding of cancers, particularly in how they develop resistance to therapies and how we can ‘outsmart’ them using gene editing or different therapeutic pathways, but also… Read More

#Cancer Research #Editor's Choice #News

#Diagnostics #Genomics #Personalised medicine #Precision medicine #Predictive diagnostics

Predictive diagnostics: closing the precision medicine gap

Listen to this article on the DDW podcast: Jarret Glasscock, PhD, CEO of Cofactor Genomics explains how diagnostics are emerging as the key to ensuring the right patients get matched to the right therapy, at the right time.  Precision medicine promises a paradigm shift to confidently match the right patients… Read More

#Exclusive Content

#AI #Drug Discovery 2022 #Genomics #Immunology #Nanomedicine / nanotechnology #Personalised medicine

Sharing knowledge to fuel the revolution

Here, we speak with two of the keynote speakers at this year’s Drug Discovery 2022, Molly Stevens, Professor of Biomedical Materials and Regenerative Medicine at Imperial College London, and Rab Prinjha, VP Head of Immunology Research Unit at GlaxoSmithKline, about the insights they will be sharing and what they see as the… Read More

#Exclusive Content

#Cancer research #Clinical trials #Drug development #Molecular research #Oncology #Personalised medicine

Exclusive: The personalised medicine paradigm

Since the turn of the century, when the term “personalised medicine” was first coined, the use of molecular diagnostic (or biomarker) testing in clinical trials has continued to grow in terms of complexity and importance. These tests have undergone a period of rapid development and growth in the last decade, with the implementation… Read More

#Editor's Choice #Exclusive Content #News